Compare VBNK & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VBNK | SCTX |
|---|---|---|
| Founded | 1980 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 622.7M | 536.5M |
| IPO Year | 2016 | 2026 |
| Metric | VBNK | SCTX |
|---|---|---|
| Price | $22.53 | $15.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $25.50 | ★ $57.00 |
| AVG Volume (30 Days) | 81.7K | ★ 428.1K |
| Earning Date | 12-09-2026 | 11-29-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.02 | N/A |
| Revenue Next Year | $37.94 | N/A |
| P/E Ratio | $25.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.25 | $13.50 |
| 52 Week High | $24.42 | $39.60 |
| Indicator | VBNK | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.24 | 37.51 |
| Support Level | $21.51 | $13.50 |
| Resistance Level | $23.24 | $22.07 |
| Average True Range (ATR) | 0.60 | 2.12 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 26.73 | 13.28 |
VersaBank is a Schedule I Canadian bank that provides mainly commercial lending and banking services to select niche markets in Canada and the United States. Its products and services include credit assets, deposits, and cybersecurity services through its wholly owned subsidiary. The bank operates through four segments: Digital Banking Canada and Digital Banking USA, both using a business-to-business model with proprietary financial technology to serve underserved markets; DRTC, which provides cybersecurity services and banking and financial technology development; and Digital Meteor, which owns proprietary technology supporting next-generation digital assets, including Real Bank Deposit Tokens (RBDTs). The majority of revenue comes from Digital Banking.
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.